IDEXX Laboratories, Inc. (NASDAQ:IDXX) to Post Q4 2024 Earnings of $2.62 Per Share, William Blair Forecasts

IDEXX Laboratories, Inc. (NASDAQ:IDXX) – Equities researchers at William Blair lowered their Q4 2024 EPS estimates for IDEXX Laboratories in a research note issued on Wednesday, May 1st. William Blair analyst R. Daniels now forecasts that the company will post earnings of $2.62 per share for the quarter, down from their prior estimate of $2.70. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for IDEXX Laboratories’ current full-year earnings is $11.12 per share. William Blair also issued estimates for IDEXX Laboratories’ Q1 2025 earnings at $3.08 EPS, Q2 2025 earnings at $3.22 EPS, Q3 2025 earnings at $3.16 EPS, Q4 2025 earnings at $3.17 EPS and FY2025 earnings at $12.63 EPS.

Several other equities research analysts have also weighed in on IDXX. Piper Sandler lowered IDEXX Laboratories from an “overweight” rating to a “neutral” rating and set a $525.00 price objective for the company. in a report on Tuesday, January 30th. Barclays cut their target price on IDEXX Laboratories from $655.00 to $570.00 and set an “overweight” rating for the company in a research note on Thursday. The Goldman Sachs Group lifted their price target on IDEXX Laboratories from $500.00 to $650.00 and gave the company a “buy” rating in a research report on Wednesday, January 17th. JPMorgan Chase & Co. lifted their price target on IDEXX Laboratories from $600.00 to $630.00 and gave the company an “overweight” rating in a research report on Tuesday, February 6th. Finally, StockNews.com downgraded IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Thursday. Four investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, IDEXX Laboratories presently has an average rating of “Moderate Buy” and a consensus target price of $580.88.

IDEXX Laboratories Trading Up 1.0 %

NASDAQ IDXX opened at $480.60 on Thursday. IDEXX Laboratories has a 12 month low of $372.50 and a 12 month high of $583.39. The firm has a market capitalization of $39.91 billion, a P/E ratio of 46.52, a PEG ratio of 3.66 and a beta of 1.27. The business has a fifty day simple moving average of $525.21 and a 200 day simple moving average of $512.07. The company has a current ratio of 1.57, a quick ratio of 1.17 and a debt-to-equity ratio of 0.40.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Monday, February 5th. The company reported $2.32 earnings per share for the quarter, beating the consensus estimate of $2.12 by $0.20. IDEXX Laboratories had a net margin of 23.26% and a return on equity of 63.66%. The firm had revenue of $901.60 million during the quarter, compared to the consensus estimate of $891.88 million. During the same period in the previous year, the firm posted $2.05 earnings per share. The business’s revenue was up 8.8% compared to the same quarter last year.

Insiders Place Their Bets

In other IDEXX Laboratories news, CFO Brian P. Mckeon sold 23,326 shares of IDEXX Laboratories stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $570.01, for a total value of $13,296,053.26. Following the transaction, the chief financial officer now directly owns 29,718 shares of the company’s stock, valued at approximately $16,939,557.18. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, SVP George Fennell sold 8,198 shares of the business’s stock in a transaction that occurred on Thursday, February 8th. The stock was sold at an average price of $573.87, for a total transaction of $4,704,586.26. Following the transaction, the senior vice president now directly owns 6,712 shares of the company’s stock, valued at $3,851,815.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Brian P. Mckeon sold 23,326 shares of IDEXX Laboratories stock in a transaction that occurred on Wednesday, February 7th. The shares were sold at an average price of $570.01, for a total value of $13,296,053.26. Following the sale, the chief financial officer now owns 29,718 shares in the company, valued at $16,939,557.18. The disclosure for this sale can be found here. Insiders have sold 43,524 shares of company stock valued at $24,871,960 in the last ninety days. Company insiders own 2.11% of the company’s stock.

Institutional Investors Weigh In On IDEXX Laboratories

Several hedge funds have recently made changes to their positions in IDXX. OFI Invest Asset Management bought a new stake in shares of IDEXX Laboratories during the third quarter valued at approximately $25,000. Valley National Advisers Inc. boosted its position in shares of IDEXX Laboratories by 84.6% during the fourth quarter. Valley National Advisers Inc. now owns 48 shares of the company’s stock valued at $26,000 after purchasing an additional 22 shares in the last quarter. Riverview Trust Co bought a new stake in shares of IDEXX Laboratories during the first quarter valued at approximately $26,000. Geo Capital Gestora de Recursos Ltd bought a new stake in IDEXX Laboratories in the third quarter worth $28,000. Finally, Covestor Ltd boosted its holdings in IDEXX Laboratories by 71.8% in the third quarter. Covestor Ltd now owns 67 shares of the company’s stock worth $29,000 after acquiring an additional 28 shares in the last quarter. 87.84% of the stock is currently owned by institutional investors.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.